My approach to patient care is to hopefully make a difference in my patients' lives, one patient at a...
My approach to patient care is to hopefully make a difference in my patients' lives, one patient at a time. I value my patients and do my best to provide them with compassion and respect, as well as apply my expertise and best judgment to their particular health issue.
Most important, I build long-term relationships with my patients during the management of their life-altering diseases. I am always upfront with my patients – together, we make collaborative decisions regarding their best possible treatment options and care.
Conditions I treat are:
- Anemias, including sickle cell anemia
- Hemostasis and thrombosis disorders
- General hematology
- Essential thrombocythemia
- Polycythemia vera
Associate Professor - Department of Medicine, Hematology/Oncology (SMD)
Residency & Fellowship
Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2010 - 2013
Residency, Internal Medicine, Johns Hopkins Bayview Medical Center. 2008 - 2010
Internship, Internal Medicine, Johns Hopkins Bayview Medical Center. 2007 - 2008
MD | University of Rochester School of Medicine/Dentistry. 2007
Wilmot Cancer Research Fellowship. 2013 - 2016
American Society of Clinical Oncology (ASCO) Resident Ravel Award (RTA). 2010
University of Rochester School of Medicine Summer Research Fellowship. 2004
Jonas E. Salk Scholarship Award for Research and Academic Excellence. 2003
Phi Beta Kappa National Honor Society. 2003
Sigma Xi Scientific Research Society. 2003
Minority Access to Research Careers (MARC) Scholarship. 2002 - 2003
Eugene Lang Student-Faculty Research Award. 2002
Stephen Bucholz Award for Biological Sciences. 2002
Golden Key International Honor Society. 2002
Deans' List. 1999 - 2003
Lead Researcher: Frank Akwaa
Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disease that can affect some people once, but it can be a recurrent problem with chronic issues for others. This study will help us understand why this is the case. Blood samples and data wi...
A Case-Based Approach to Transition of Care for Patients With Sickle Cell Disease
Noronha SA, Pulcino TL, Akwaa F.
South Medical Journal. 2016; 109(9): 531-4.
The potential of target-specific oral anti-coagulants for the acute and long term treatment of venous thromboembolism
Akwaa, F.; Spyropoulos, AC.
Current Medical Research and Opinion. 2014; 30(11): 2179-90.
Treatment of Bleeding Complications When Using Oral Anticoagulants for Prevention of Strokes
Akwaa F, Spyropoulos AC.
Current Treatment Options in Cardiovascular Medicine. 2013; 15(3): 288-98.
Novel Oral Anticoagulants: A Review of the Literature and Considerations in Special Clinical Situations
Akwaa F, Spyropoulos.
Hospital Practice. 2013; 41(1): 8-18.
Surrogate end points for long-term outcomes in chronic myeloid leukemia
Akwaa F, Liesveld, J.
Leukemia & Lymphoma. 2013; 54(10): 2103-11.
A Pilot Study of Music Therapy in Huntington's Disease
Hyson C, Oliva R, LaDonna KA, Akwaa F, Richards J, Sahler OJ.
Journal of Neurology, Neurosurgery & Psychiatry. 2005; 76(10 (Supp 4)).
Factors binding a non-classical cis-element prevent heterochromatin effects on locus control region activity.
Harrow F, Amuta JU, Hutchinson SR, Akwaa F, Ortiz BD.
J Biol Chem. 2004; 279(17): 17842-9.